Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Eli Lilly Expands Biotech Incubator Network with New San Diego Site

Eli Lilly Expands Biotech Incubator Network with New San Diego Site

Eli Lilly and Company has officially opened its latest Gateway Labs incubator site in San Diego, marking a significant expansion of the pharmaceutical giant's commitment to fostering innovation in the biotech sector. The new facility, which opened on September 26, 2025, is set to become a hub for collaboration between early-stage biotechs and Lilly's established research infrastructure.

NoahAI News9/26/2025
Lotus Pharmaceuticals Acquires Alvogen in $2 Billion Deal, Expands US Presence

Lotus Pharmaceuticals Acquires Alvogen in $2 Billion Deal, Expands US Presence

Taiwan-based Lotus Pharmaceuticals has acquired a 100% equity stake in Alvogen, transforming the New Jersey-based company into a subsidiary. The deal, valued at up to $2 billion, catapults Lotus into the ranks of the top 20 specialty pharmaceutical companies worldwide and significantly expands its presence in the United States.

NoahAI News9/26/2025
US Biotechs Hesitant on European Licensing Deals Amid Drug Pricing Controversies

US Biotechs Hesitant on European Licensing Deals Amid Drug Pricing Controversies

US biotechnology companies are increasingly reluctant to license their drugs to European partners, fearing potential backlash from the Trump administration's drug pricing initiatives. This development comes as pharmaceutical companies face growing pressure on both sides of the Atlantic over drug pricing and access.

NoahAI News9/26/2025
FDA Approves Crinetics' Palsonify, Marking New Era in Acromegaly Treatment

FDA Approves Crinetics' Palsonify, Marking New Era in Acromegaly Treatment

The U.S. Food and Drug Administration (FDA) has granted approval to Crinetics Pharmaceuticals' Palsonify (paltusotine), ushering in a potentially transformative treatment option for patients with acromegaly. This milestone marks Crinetics' entry into the commercial pharmaceutical market and represents a significant advancement in the management of this rare endocrine disorder.

NoahAI News9/26/2025
Eli Lilly's Inluriyo Gains FDA Approval, Marking Second Oral SERD for Breast Cancer Treatment

Eli Lilly's Inluriyo Gains FDA Approval, Marking Second Oral SERD for Breast Cancer Treatment

Eli Lilly has secured FDA approval for Inluriyo (imlunestrant), its oral selective estrogen receptor degrader (SERD) for the treatment of advanced breast cancer. This marks the second approval in this drug class, following Menarini Group's Orserdu, and represents a significant advancement in breast cancer therapy.

NoahAI News9/26/2025
Heartflow's AI-Powered Plaque Analysis Platform Receives FDA Clearance and Expanded Insurance Coverage

Heartflow's AI-Powered Plaque Analysis Platform Receives FDA Clearance and Expanded Insurance Coverage

Heartflow, a leader in cardiovascular diagnostics, has made significant strides in the development and adoption of its artificial intelligence-powered plaque analysis platform. The company recently secured FDA clearance for an updated version of its algorithm and gained expanded insurance coverage, marking important milestones in its quest to revolutionize coronary artery disease assessment.

NoahAI News9/26/2025
Pennsylvania Pharma Job Market Shows Mixed Signals Amid Industry Shifts

Pennsylvania Pharma Job Market Shows Mixed Signals Amid Industry Shifts

The pharmaceutical industry in Pennsylvania is experiencing a complex landscape of job opportunities, reflecting broader trends in the life sciences sector. While overall job postings have seen a significant decline, several major companies are actively hiring, offering a glimmer of hope for job seekers in the region.

NoahAI News9/26/2025
Quest to Distribute Guardant's Innovative Cancer Blood Test, Expanding Access and Detection Capabilities

Quest to Distribute Guardant's Innovative Cancer Blood Test, Expanding Access and Detection Capabilities

In a significant move for cancer screening accessibility, Guardant Health and Quest Diagnostics have announced a collaboration to offer Guardant's Shield blood-based colorectal cancer test through Quest's extensive distribution network. This partnership, set to commence in the first quarter of 2026, will allow physicians to order the test through their Quest accounts and electronic health records, potentially increasing early detection rates for colorectal cancer.

NoahAI News9/26/2025
Immuneering's Atebimetinib Shows Promise in Pancreatic Cancer Treatment

Immuneering's Atebimetinib Shows Promise in Pancreatic Cancer Treatment

Immuneering Corporation has reported encouraging results from a mid-stage study of its investigational deep cyclic inhibitor, atebimetinib, in pancreatic cancer patients. The data, presented on Wednesday, demonstrates significant improvements in overall survival and progression-free survival rates compared to standard of care treatments.

NoahAI News9/26/2025
Lilly Halts Muscle-Sparing Obesity Drug Trial, Signaling Shift in FDA Approval Standards

Lilly Halts Muscle-Sparing Obesity Drug Trial, Signaling Shift in FDA Approval Standards

Eli Lilly has terminated a Phase IIb clinical trial for bimagrumab, an experimental muscle-sparing obesity drug, citing "strategic business reasons." This decision comes amid indications of potentially higher approval standards from the U.S. Food and Drug Administration (FDA) for drugs aimed at preserving muscle mass in patients taking weight loss medications.

NoahAI News9/26/2025
Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

Pharmaceutical Industry Faces Widespread Layoffs Amid Strategic Shifts and Market Pressures

The pharmaceutical and biotech sectors are experiencing a significant wave of workforce reductions as companies across the industry grapple with financial pressures, pipeline reprioritizations, and strategic realignments. This comprehensive overview examines the latest developments in layoffs, restructuring efforts, and their implications for the industry landscape.

NoahAI News9/26/2025
Harmony's Fragile X Syndrome Trial Failure Raises Questions About ZYN002's Future

Harmony's Fragile X Syndrome Trial Failure Raises Questions About ZYN002's Future

Harmony Biosciences faced a significant setback as its pivotal Phase III RECONNECT trial for ZYN002, a synthetic cannabidiol gel targeting fragile X syndrome, failed to meet its primary efficacy endpoint. The trial's disappointing results have cast doubt on the future of the drug candidate and led to a substantial drop in the company's stock price.

NoahAI News9/26/2025
«1...454647...67»